Thiazolidinediones Increase Plasma-Adipose Tissue FFA Exchange Capacity and Enhance Insulin-Mediated Control of Systemic FFA Availability
- 1 May 2001
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 50 (5) , 1158-1165
- https://doi.org/10.2337/diabetes.50.5.1158
Abstract
We studied the effects of thiazolidinedione treatment (rosiglitazone 1 or 10 μmol · kg−1 · day−1 or darglitazone 1.3 μmol · kg−1 · day−1 for 3 weeks) on lipid metabolism in obese Zucker rats. In the basal 7-h fasted state, rosiglitazone (10 μmol · kg−1 · day−1) and darglitazone corrected the hypertriglyceridemia by increasing plasma triglyceride (TG) clearance and decreasing hepatic TG production, as assessed using Triton WR 1339. Free fatty acid (FFA) metabolism was assessed using 3H-palmitate tracer by estimating rates of plasma FFA appearance (Ra), whole-body FFA oxidation (Rox), and tissue-specific nonoxidative FFA disposal (Rfs). Basal Ra, plasma FFA levels, and clearance were increased by both thiazolidinediones. Detailed studies were conducted with darglitazone, which under basal conditions increased Ra (+114%), Rox (+51%), and Rfs in adipose tissues. During euglycemic clamps performed at insulin levels corresponding to those observed postprandially, darglitazone increased the glucose infusion rate from 4.7 to 13.3 mg · min−1 and, in contrast to the basal state, it decreased Ra (−67%), Rox (−84%), and Rfs in adipose tissue, muscle, and liver. We concluded that thiazolidinediones 1) ameliorate hypertriglyceridemia by lowered hepatic TG production and augmented TG clearance (two separate kinetic effects), 2) enhance insulin-mediated suppression of systemic FFA mobilization while increasing the capacity to mobilize FFA during fasting, 3) increase FFA trafficking into adipose tissue by increasing the ability of adipose tissue to take up and store FFA, and 4) enhance metabolic flexibility by improving glucoregulation under hyperinsulinemic conditions (possibly involving reduced skeletal muscle and liver exposure to fatty acids) and augmenting the capacity to utilize FFAs during fasting.Keywords
This publication has 32 references indexed in Scilit:
- Role of Skeletal Muscle in Thiazolidinedione Insulin Sensitizer (PPAR Agonist) ActionEndocrinology, 1998
- NUTRITIONAL AND HORMONAL REGULATION OF ENZYMES IN FAT SYNTHESIS: Studies of Fatty Acid Synthase and Mitochondrial Glycerol-3-Phosphate Acyltransferase Gene TranscriptionAnnual Review of Nutrition, 1998
- Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.Journal of Clinical Investigation, 1998
- Glucose plus insulin regulate fat oxidation by controlling the rate of fatty acid entry into the mitochondria.Journal of Clinical Investigation, 1996
- The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiationBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM: effects of dietary fructose alone or in combination with pioglitazoneDiabetes, 1996
- Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulinDiabetes, 1995
- A [3H]2-deoxyglucose method for comparing rates of glucose metabolism and insulin responses among rat tissues in vivo. Validation of the model and the absence of an insulin effect on brainDiabetes, 1984
- Studies on antidiabetic agents. II. Synthesis of 5-(4-(1-methylcyclohexylmethoxy)-benzyl)thiazolidine-2,4-dione (ADD-3878) and its derivatives.CHEMICAL & PHARMACEUTICAL BULLETIN, 1982
- THE GLUCOSE FATTY-ACID CYCLE ITS ROLE IN INSULIN SENSITIVITY AND THE METABOLIC DISTURBANCES OF DIABETES MELLITUSPublished by Elsevier ,1963